IMAB – I-Mab ADR
I-MABIMAB
$2.62Name : I-MAB
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $213,949,984.00
EPSttm : -0.55
I-MAB
$2.62
30.35%$0.61Float Short %
0.76
Margin Of Safety %
Put/Call OI Ratio
0.22
EPS Next Q Diff
EPS Last/This Y
0.08
EPS This/Next Y
-0.11
Price
2.62
Target Price
6
Analyst Recom
1
Performance Q
200.29
Relative Volume
76.96
Beta
1.38
Ticker: IMAB
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-07-04 | IMAB | 2.15 | 0.36 | 7.13 | 1620 |
| 2025-07-07 | IMAB | 2.1 | 0.32 | 0.10 | 1585 |
| 2025-07-08 | IMAB | 2.2 | 0.30 | 0.01 | 1590 |
| 2025-07-09 | IMAB | 2.32 | 0.31 | 0.33 | 1574 |
| 2025-07-10 | IMAB | 2.06 | 0.30 | 0.07 | 1584 |
| 2025-07-11 | IMAB | 2.12 | 0.30 | 0.00 | 1608 |
| 2025-07-14 | IMAB | 2.1514 | 0.30 | 999.99 | 1608 |
| 2025-07-15 | IMAB | 2.11 | 0.29 | 0.25 | 1598 |
| 2025-07-16 | IMAB | 2.16 | 0.30 | 999.99 | 1583 |
| 2025-07-17 | IMAB | 2.15 | 0.30 | 999.99 | 1583 |
| 2025-07-18 | IMAB | 2.1 | 0.33 | 0.18 | 1618 |
| 2025-07-21 | IMAB | 2.13 | 0.30 | 0.33 | 475 |
| 2025-07-22 | IMAB | 2.08 | 0.30 | 0.00 | 484 |
| 2025-07-23 | IMAB | 2.07 | 0.30 | 0.00 | 484 |
| 2025-07-24 | IMAB | 2.11 | 0.30 | 0.00 | 485 |
| 2025-07-25 | IMAB | 2.09 | 0.29 | 999.99 | 498 |
| 2025-07-28 | IMAB | 1.86 | 0.30 | 4.50 | 499 |
| 2025-07-29 | IMAB | 1.68 | 0.32 | 0.00 | 510 |
| 2025-07-30 | IMAB | 2 | 0.31 | 0.05 | 514 |
| 2025-07-31 | IMAB | 2.01 | 0.25 | 0.02 | 635 |
| 2025-08-01 | IMAB | 2.62 | 0.22 | 0.23 | 690 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-07-04 | IMAB | 2.15 | - | - | -0.20 |
| 2025-07-07 | IMAB | 2.10 | - | - | -0.20 |
| 2025-07-08 | IMAB | 2.20 | - | - | -0.20 |
| 2025-07-09 | IMAB | 2.31 | - | - | -0.20 |
| 2025-07-10 | IMAB | 2.05 | - | - | -0.20 |
| 2025-07-11 | IMAB | 2.13 | - | - | -0.20 |
| 2025-07-14 | IMAB | 2.14 | - | - | -0.20 |
| 2025-07-15 | IMAB | 2.10 | - | - | -0.20 |
| 2025-07-16 | IMAB | 2.15 | - | - | -0.20 |
| 2025-07-17 | IMAB | 2.16 | - | - | -0.20 |
| 2025-07-18 | IMAB | 2.11 | - | - | -0.20 |
| 2025-07-21 | IMAB | 2.12 | - | - | -0.20 |
| 2025-07-22 | IMAB | 2.09 | - | - | -0.20 |
| 2025-07-23 | IMAB | 2.11 | - | - | -0.20 |
| 2025-07-24 | IMAB | 2.12 | - | - | -0.20 |
| 2025-07-25 | IMAB | 2.11 | - | - | -0.20 |
| 2025-07-28 | IMAB | 1.86 | - | - | -0.20 |
| 2025-07-29 | IMAB | 1.70 | - | - | -0.20 |
| 2025-07-30 | IMAB | 2.03 | - | - | -0.20 |
| 2025-07-31 | IMAB | 2.01 | - | - | -0.20 |
| 2025-08-01 | IMAB | 2.62 | - | - | -0.20 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-07-04 | IMAB | 0.00 | -42.89 | 0.48 |
| 2025-07-07 | IMAB | 0.00 | -43.46 | 0.48 |
| 2025-07-08 | IMAB | 0.00 | -43.46 | 0.48 |
| 2025-07-09 | IMAB | 0.00 | -43.46 | 0.48 |
| 2025-07-10 | IMAB | 0.00 | -43.46 | 0.48 |
| 2025-07-11 | IMAB | 0.00 | -43.46 | 0.94 |
| 2025-07-14 | IMAB | 0.00 | -43.46 | 0.94 |
| 2025-07-15 | IMAB | 0.00 | -43.46 | 0.94 |
| 2025-07-16 | IMAB | 0.00 | -43.46 | 0.94 |
| 2025-07-17 | IMAB | 0.00 | -43.46 | 0.94 |
| 2025-07-18 | IMAB | 0.00 | -43.46 | 0.94 |
| 2025-07-21 | IMAB | 0.00 | -43.46 | 0.94 |
| 2025-07-22 | IMAB | 0.00 | -43.46 | 0.94 |
| 2025-07-23 | IMAB | 0.00 | -43.46 | 0.94 |
| 2025-07-24 | IMAB | 0.00 | -43.46 | 0.94 |
| 2025-07-25 | IMAB | 0.00 | -43.46 | 0.76 |
| 2025-07-28 | IMAB | 0.00 | -42.01 | 0.76 |
| 2025-07-29 | IMAB | 0.00 | -42.01 | 0.76 |
| 2025-07-30 | IMAB | 0.00 | -42.01 | 0.76 |
| 2025-07-31 | IMAB | 0.00 | -42.01 | 0.76 |
| 2025-08-01 | IMAB | 0.00 | -42.01 | 0.76 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
Avg. EPS Est. Current Quarter
-0.05
Avg. EPS Est. Next Quarter
-0.05
Insider Transactions
Institutional Transactions
-42.01
Beta
1.38
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
15
Growth Score
18
Sentiment Score
65
Actual DrawDown %
96.9
Max Drawdown 5-Year %
-99.3
Target Price
6
P/E
Forward P/E
PEG
P/S
P/B
1.08
P/Free Cash Flow
EPS
-0.71
Average EPS Est. Cur. Y
-0.2
EPS Next Y. (Est.)
-0.31
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
Relative Volume
76.96
Return on Equity vs Sector %
-28.3
Return on Equity vs Industry %
-9.7
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.02
EBIT Estimation
I-MABSector: Healthcare
Industry: Biotechnology
Employees: 32
I-Mab, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment of solid tumors. It has a strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell, and offer to sell FE301, an interleukin-6 inhibitor. The company also has collaborations with Bristol Myers Squibb for the development of givastomig; ABL Bio, Inc. for the development of givastomig and ragistomig; and TJ Bio for the development of uliledlimab. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland.
stock quote shares IMAB – I-Mab ADR Stock Price stock today
news today IMAB – I-Mab ADR stock forecast ,stock prediction 2023 2024 2025
marketwatch IMAB – I-Mab ADR yahoo finance google finance
stock history IMAB – I-Mab ADR invest stock market
stock prices IMAB premarket after hours
ticker IMAB fair value insiders trading